US7393529B2
(en)
|
1998-04-09 |
2008-07-01 |
Idexx Laboratories, Inc. |
Methods and compositions for inhibiting binding of IgE to a high affinity receptor
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
GB0022101D0
(en)
*
|
2000-09-08 |
2000-10-25 |
Phogen Ltd |
Delivery of substances to cells
|
KR100980153B1
(ko)
|
2000-11-29 |
2010-09-03 |
피씨아이 바이오테크 에이에스 |
사이토졸 내로의 분자 전달을 위한 광화학적 내부이행
|
WO2002044395A1
(en)
|
2000-11-29 |
2002-06-06 |
Pci Biotech As |
Photochemical internalization for virus-mediated molecule delivery into the cyosol
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
CA2535799A1
(en)
|
2003-08-15 |
2005-03-03 |
University Of Florida |
Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
|
GB0321311D0
(en)
*
|
2003-09-12 |
2003-10-15 |
Phogen Ltd |
Delivery of substances to cells
|
CN102321584B
(zh)
|
2003-12-31 |
2014-01-08 |
宾夕法尼亚州研究基金会 |
预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
|
EP1720568A2
(de)
*
|
2004-02-19 |
2006-11-15 |
Coley Pharmaceutical Group, Inc. |
Immunstimulatorische virale rna-oligonucleotide
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
US20060040882A1
(en)
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
DE602005026811D1
(de)
|
2004-06-22 |
2011-04-21 |
Univ Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
WO2007002718A2
(en)
|
2005-06-27 |
2007-01-04 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of hif-1 and theraputic uses thereof
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
EP3360965A1
(de)
|
2006-01-20 |
2018-08-15 |
Cell Signaling Technology, Inc. |
Translokation und mutante ros-kinase in humanem nichtkleinzelligem bronchialkarzinom
|
EP1993611A4
(de)
|
2006-03-16 |
2013-05-22 |
Alnylam Pharmaceuticals Inc |
Rnai-modulation von tgf-beta und ihre therapeutische verwendung
|
WO2007115168A2
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
EP2447360A1
(de)
|
2006-04-14 |
2012-05-02 |
Cell Signaling Technology, Inc. |
Gendefekte und Mutante ALK-Kinase in festen menschlichen Tumoren
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
KR101670085B1
(ko)
|
2006-07-21 |
2016-10-28 |
사일런스 테라퓨틱스 게엠베하 |
단백질 키나아제 3의 발현을 억제하기 위한 수단
|
WO2008015841A1
(fr)
*
|
2006-08-02 |
2008-02-07 |
Yoshio Umezawa |
Protéine de fusion inhibitrice de kinase et préparation pharmaceutique
|
EP2062049B1
(de)
|
2006-09-06 |
2014-04-30 |
The Regents of the University of California |
Molekulare diagnose und klassifikation bösartiger melanome
|
AU2008221383B2
(en)
|
2007-02-28 |
2012-09-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
JP5475643B2
(ja)
|
2007-05-04 |
2014-04-16 |
マリーナ バイオテック,インコーポレイテッド |
アミノ酸脂質およびその使用
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
ES2477292T3
(es)
|
2007-08-13 |
2014-07-16 |
Baxter International Inc. |
Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
|
EP3072963B1
(de)
|
2007-10-18 |
2020-04-01 |
Cell Signaling Technology, Inc. |
Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
|
CA2703165A1
(en)
|
2007-10-22 |
2009-04-30 |
The Regents Of The University Of California |
Biomarkers for prenatal diagnosis of congenital cytomegalovirus
|
ES2489840T3
(es)
|
2008-03-05 |
2014-09-02 |
The Regents Of The University Of California |
Pronóstico molecular y clasificación de melanoma maligno en base a marcadores seleccionados entre la lista que consiste en RGS1, NCOA3, SPP1, PHIP
|
CA2720363A1
(en)
|
2008-04-15 |
2009-10-22 |
Bira Arya |
Compositions and methods for delivering inhibitory oligonucleotides
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
AU2009246134B2
(en)
|
2008-05-16 |
2016-03-03 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
|
US20110212021A1
(en)
|
2008-05-30 |
2011-09-01 |
Slack Frank J |
Targeted oligonucleotide compositions for modifying gene expression
|
EP2297322A1
(de)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation der genexpression über das abzielen kleiner endogener rna auf genpromotoren
|
EP2165710A1
(de)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosinkinaserezeptor Tyro3 als therapeutisches Target bei der Behandlung eines Blasentumors
|
CN104382853A
(zh)
|
2008-10-16 |
2015-03-04 |
玛瑞纳生物技术有限公司 |
基因沉默治疗剂的脂质体有效递送方法和组合物
|
WO2010062604A2
(en)
|
2008-10-27 |
2010-06-03 |
Baxter International Inc. |
Models of thrombotic thrombocytopenic purpura and methods of use thereof
|
EP2198879A1
(de)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
|
CA2744236C
(en)
|
2009-02-12 |
2021-03-16 |
Cell Signaling Technology, Inc. |
Mutant ros expression in human cancer
|
WO2010091878A2
(en)
|
2009-02-13 |
2010-08-19 |
Silence Therapeutics Ag |
Means for inhibiting the expression of opa1
|
US8829179B2
(en)
|
2009-02-18 |
2014-09-09 |
Silence Therapeutics Gmbh |
Means for inhibiting the expression of ANG2
|
JP2012520686A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子6(STAT6)遺伝子発現のRNA干渉媒介性阻害
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
BRPI1009271A8
(pt)
|
2009-03-19 |
2016-02-10 |
Merck Sharp & Dohme |
Molécula de ácido nucleico interferente curto de filamento duplo, composição farmacêutica, e, método para tratar um indivíduo humano que sofre de uma condição que é mediada pela ação, ou pela perda de ação, de bach1
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
CN102439152A
(zh)
|
2009-03-27 |
2012-05-02 |
默沙东公司 |
使用短干扰核酸(siNA)的RNA干扰介导的细胞间粘附分子1(ICAM-1)基因表达的抑制
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
JP2012521760A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いたアポトーシスシグナル調節キナーゼ1(ASK1)遺伝子発現のRNA干渉媒介性阻害
|
EP2411520A2
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
|
EP2411018A2
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der nervenwachstumsfaktor-betaketten (ngf9-gen-expression mittels sina (short interfering nucleic acid)
|
US20120149756A1
(en)
|
2009-04-10 |
2012-06-14 |
Associatin Institut de Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
EP2421972A2
(de)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
|
EP2266550A1
(de)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
|
KR101692063B1
(ko)
|
2009-12-09 |
2017-01-03 |
닛토덴코 가부시키가이샤 |
hsp47 발현의 조절
|
CN108404123A
(zh)
|
2010-01-15 |
2018-08-17 |
康奈尔大学 |
降低细胞内蛋白质水平的方法
|
WO2011094759A2
(en)
|
2010-02-01 |
2011-08-04 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
WO2011139842A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
EP3190187A1
(de)
|
2010-05-21 |
2017-07-12 |
Peptimed, Inc. |
Reagenzien und verfahren zur behandlung von krebs
|
US20130149320A1
(en)
|
2010-05-31 |
2013-06-13 |
Centre National De La Recherche Scientifique |
Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
|
US9045755B2
(en)
|
2010-06-24 |
2015-06-02 |
Quark Pharmaceuticals, Inc. |
Double stranded RNA compounds to RhoA and use thereof
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
CA2807440A1
(en)
|
2010-08-04 |
2012-02-09 |
Cizzle Biotechnology Limited |
Methods and compounds for the diagnosis and treatment of cancer
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
US9233997B2
(en)
|
2010-08-26 |
2016-01-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
|
WO2012047631A2
(en)
|
2010-09-27 |
2012-04-12 |
The Children's Hospital Of Philadelphia |
Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
|
US20130267029A1
(en)
|
2010-10-01 |
2013-10-10 |
Fundacion Centro Nacional de Ivestigaciones Oncologicas, Carlos |
Manipulation of stem cell function by p53 isoforms
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012061443A2
(en)
|
2010-11-01 |
2012-05-10 |
NanoOncology, Inc. |
Compositions of a peptide-based system for cell-specific targeting
|
EP2455456A1
(de)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
|
BR112013020875A2
(pt)
|
2011-02-15 |
2019-09-24 |
Immune Design Corp |
método para indução de uma resposta imune específica para um imunógeno em um indivíduo.
|
WO2012118910A2
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
WO2012175481A1
(en)
|
2011-06-20 |
2012-12-27 |
Institut Curie |
Compositions and methods for treating leukemia
|
EP2557089A2
(de)
|
2011-07-15 |
2013-02-13 |
Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Zusammensetzungen und Verfahren zur Immunmodulation
|
DK2581448T3
(en)
|
2011-10-13 |
2015-04-27 |
Ass Inst De Myologie |
Tricyclo-DNA phosphorothioate
|
CN104080797A
(zh)
|
2011-11-11 |
2014-10-01 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
CN104080912A
(zh)
|
2012-01-12 |
2014-10-01 |
夸克制药公司 |
用于治疗听力和平衡障碍的组合疗法
|
EP2617434A1
(de)
|
2012-01-20 |
2013-07-24 |
Laboratorios Del. Dr. Esteve, S.A. |
HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
|
WO2013123996A1
(en)
|
2012-02-24 |
2013-08-29 |
Astrazeneca Uk Limited |
Novel sirna inhibitors of human icam-1
|
DK2838998T3
(en)
|
2012-04-18 |
2018-01-15 |
Cell Signaling Technology Inc |
EGFR AND ROS1 IN CANCER
|
JP6364009B2
(ja)
|
2012-09-12 |
2018-07-25 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
P53に対する二本鎖オリゴヌクレオチド分子、およびその使用方法
|
EP2895608B1
(de)
|
2012-09-12 |
2018-12-05 |
Quark Pharmaceuticals, Inc. |
Doppelsträngige oligonukleotidmoleküle an p53 und verfahren zur verwendung davon
|
EP2961843A2
(de)
|
2013-02-28 |
2016-01-06 |
Arrowhead Research Corporation |
Organische zusammensetzungen zur behandlung von epas1-bedingten erkrankungen
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
UY35368A
(es)
|
2013-03-08 |
2014-10-31 |
Irm Llc |
Péptidos y composiciones para el tratamiento de daño articular
|
WO2014154898A1
(en)
|
2013-03-29 |
2014-10-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Prognosis and treatment of cancers
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
EP2853595A1
(de)
|
2013-09-30 |
2015-04-01 |
Soluventis GmbH |
NOTCH 1-spezifische siRNA-Moleküle
|
AU2015218365A1
(en)
|
2014-02-14 |
2016-09-01 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
CU24392B1
(es)
|
2014-05-13 |
2019-04-04 |
Novartis Ag |
Compuestos y composiciones para inducir condrogénesis
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
AU2015289773A1
(en)
|
2014-07-15 |
2017-02-02 |
Immune Design Corp. |
Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
|
AU2015307186A1
(en)
|
2014-08-27 |
2017-04-13 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016083624A1
(en)
|
2014-11-28 |
2016-06-02 |
Silence Therapeutics Gmbh |
Means for inhibiting the expression of edn1
|
CA2979703A1
(en)
|
2015-03-17 |
2016-09-22 |
Arrowhead Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression of factor xii
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
CN108064156B
(zh)
|
2015-05-29 |
2022-02-01 |
箭头药业股份有限公司 |
抑制Hif2α基因表达的组合物及方法
|
CN108271387B
(zh)
|
2015-08-07 |
2023-06-27 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
EP3156497A1
(de)
|
2015-10-16 |
2017-04-19 |
Centre National de la Recherche Scientifique (C.N.R.S.) |
Trpv2 als biomarker und als therapeutisches target für melanome
|
EP3445385A4
(de)
|
2016-04-18 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
An der progression nichtalkoholischer steatohepatitis (nash) beteiligte therapeutische ziele
|
CN109526222B
(zh)
|
2016-06-06 |
2022-04-29 |
箭头药业股份有限公司 |
5’-环膦酸酯修饰核苷酸
|
EP3269734A1
(de)
|
2016-07-15 |
2018-01-17 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Verfahren und zusammensetzungen zur behandlung von krebs
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
CA3045045A1
(en)
|
2017-01-10 |
2018-07-19 |
Zhen Li |
Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
|
BR112019023650A2
(pt)
|
2017-07-06 |
2020-06-02 |
Arrowhead Pharmaceuticals, Inc. |
Agentes rnai para inibir a expressão de alfa-enac e métodos de uso
|
EP3449978A1
(de)
|
2017-09-01 |
2019-03-06 |
Universite Paris Descartes |
Inhibitoren des arylkohlenwasserstoffrezeptors zur behandlung von weichteilsarkom und prävention von neurofibromwachstum und/oder transformation auf malignen peripheren nervenscheidentumoren
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
US10995335B2
(en)
|
2017-09-14 |
2021-05-04 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
CN111212909A
(zh)
|
2017-10-17 |
2020-05-29 |
箭头药业股份有限公司 |
用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
AU2020219355A1
(en)
|
2019-02-07 |
2021-09-30 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for Hepatitis B virus infection
|
WO2020187998A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
CA3132170A1
(en)
|
2019-04-18 |
2020-10-22 |
Michael BIERMER |
Combination therapy for treating hepatitis b virus infection
|
WO2020214974A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
CN114340664A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
EP3808763A1
(de)
|
2019-10-17 |
2021-04-21 |
Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Verbindungen zur immunmodulation
|
EP4114944A1
(de)
|
2020-03-04 |
2023-01-11 |
Ninovax |
Produkte zur unterdrückung oder verringerung der expression oder aktivität einer snorna und verwendungen davon bei der behandlung von krebs
|
TW202146011A
(zh)
|
2020-03-05 |
2021-12-16 |
美商詹森藥物公司 |
治療b型肝炎病毒感染之組合療法
|
KR20220158011A
(ko)
|
2020-03-26 |
2022-11-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
|
US20210403908A1
(en)
|
2020-06-22 |
2021-12-30 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis d virus infection
|
TW202218687A
(zh)
|
2020-09-11 |
2022-05-16 |
美商愛羅海德製藥公司 |
骨骼肌遞送載體及其使用方法
|
UY39417A
(es)
|
2020-09-11 |
2022-03-31 |
Arrowhead Pharmaceuticals Inc |
Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso
|
UY39420A
(es)
|
2020-09-11 |
2022-03-31 |
Arrowhead Pharmaceuticals Inc |
Conjugados lipídicos para el transporte de agentes terapéuticos
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
WO2022152869A1
(en)
|
2021-01-15 |
2022-07-21 |
Janssen Sciences Ireland Unlimited Company |
Use of oligonucleotides for individuals with hepatic impairment
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
CA3224600A1
(en)
|
2021-07-09 |
2023-01-12 |
Glaxosmithkline Intellectual Property (No.3) Limited |
Use of oligonucleotides for individuals with renal impairment
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
WO2023245060A2
(en)
|
2022-06-15 |
2023-12-21 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
|